Illumina Sues Premaitha Health Over NIPT IP; Swiss Firm Adopts Premaitha's Iona CE-IVD Test

Mar 16, 2015

|

NEW YORK (GenomeWeb) – Illumina and its wholly-owned subsidiary Verinata Health have filed a patent infringement suit against Premaitha Health over IP relating to non-invasive prenatal testing, the companies said today.

The suit, filed in the High Court of Justice, Chancery Division, Patents Court in the UK, asserts European Patent (UK) 0 994 963 B2 and European Patent (UK) 1 981 995 B1, both relating to the use of cell-free fetal DNA for NIPT.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Privacy Policy Information, Please

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

Moving the Parts About

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

This Week in Science

In Science this week: genetic overlap among many psychiatric disorders, and more.

Just Skip that Step

The Economist writes that an increasing number of scientific journals don't do peer review.

Main menu